Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

Summit Therapeutics (SMMT) Long-Term Debt Issuances (2021 - 2022)

Summit Therapeutics (SMMT) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $520.0 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Debt Issuances changed N/A year-over-year to $520.0 million, compared with a TTM value of $520.0 million through Sep 2023, up 1980.0%, and an annual FY2022 reading of $545.0 million, up 395.45% over the prior year.
  • Long-Term Debt Issuances was $520.0 million for Q4 2022 at Summit Therapeutics, up from $25.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $520.0 million in Q4 2022 and bottomed at $25.0 million in Q1 2022.